トップページ

 米3M、日本に車用素材拠点 

 

2006/11/9 3M

3M Reaches Agreements to Sell its Pharmaceuticals Business

3M announced today that it has entered into agreements to sell its global branded pharmaceuticals business for approximately $2.1 billion in the following regions:

Graceway Pharmaceuticals Inc. has agreed to acquire 3Ms pharmaceutical operations in the United States, Canada, and Latin America region for $875 million.
Meda AB has agreed to acquire 3Ms pharmaceutical business in Europe for $857 million. The agreement will be implemented by each 3M subsidiary subject to compliance with third party notice and approval requirements.
Ironbridge Capital and Archer Capital have agreed to acquire 3Ms pharmaceutical operations in the Asia Pacific region, including Australia and South Africa for $349 million.
The agreements are the result of a review of strategic options for the branded pharmaceuticals business and its
immune response modifier (IRM) platform that 3M announced in April. Under the agreements, the purchasers will acquire regional marketing and intellectual property rights for 3Ms well-known branded pharmaceuticals, including Aldara, Difflam, Duromine, Tambocor, Maxair, Metrogel-Vaginal and Minitran. 3Ms Drug Delivery Systems Division will be a source of supply to the acquiring companies for the products. As part of the transaction, Graceway Pharmaceuticals also will acquire the rights to certain IRM molecules.


3M Businesses
3M serves customers through six business segments, which increase speed and efficiency by sharing technological, manufacturing, marketing and other resources.

These six businesses are:
Consumer and Office Business
With powerful brands, innovative products and a global presence, we make life easier and more productive for consumers and office workers around the world.

Display and Graphics Business
Drawing on 3M's technology platforms, we provide products - display enhancement films, reflective materials, eye-catching graphics and more - that people around the world rely on every day.

Electro and Communications Business
We turn 3M technology into solutions for customers in electrical, electronics and communications markets around the world. We contribute to reliable sources of electrical power, high-performance electronic devices, and speedy and dependable telecommunications networks globally.

Health Care Business
Every day, we help improve the quality of care provided by health care professionals throughout the world. Our innovative products and services also make the delivery of patient care more affordable.

Industrial and Transportation Business
We're a global leader in tapes, abrasives, adhesives, specialty chemicals, filtration systems, and software for supply chain management. We also serve the transportation market with products for the manufacture, repair and maintenance of autos, aircraft, boats and other vehicles.

Safety, Security and Protection Services Business
Our products increase the safety, security and productivity of people, facilities and systems around the world. We
re also a leading supplier of roofing granules for asphalt shingles.


Immune Response Modifier (IRM)

3M Pharmaceuticals has a rich product development pipeline based on the Immune Response Modifier (IRM) technology platform. The IRMs are a class of unique, proprietary synthetic molecules developed by 3M Pharmaceuticals that have a broad range of potential therapeutic applications, including promising treatments for a variety of viruses and tumors.

Mechanism of Action
The IRMs are a new class of drug. They act by stimulating the body to produce cytokines, naturally occurring proteins used by cells of the immune system to communicate with each other. The cytokines induced by IRMs enhance cell-mediated immunity, a natural process by which the body controls or eliminates virus infected cells and tumor cells. Because the IRMs assist the immune system - rather than target specific viruses or tumors - they have potential uses in a wide variety of diseases. The IRMs can be formulated into many dose forms, each appropriate for a specific disease.


2007/5/7 日本経済新聞夕刊

車用素材 米3M、日本に拠点 来年にも トヨタなどと開発


 新拠点「オートモーティブセンター(仮称)」の場所は東京都内が有力。窓枠用などに塗料代替となる樹脂製の粘着テープや、エンジン回りに使う吸音・断熱材の開発を担う。顧客との試作や製品展示のスペースを設ける見通し。

 3Mは日本に住友電気工業との合弁会社、住友スリーエム(3Mの出資比率は75%)を持つ。住友スリーエムも自動車用素材を手掛けるため、新拠点の運営や製品開発で連携を検討する。


日米化学大手の自動車素材の強化策
▽ダウ・ケミカル
 近く川崎市に開発拠点。自動車素材部門トップが08年から東京に常駐へ
▽GE
 栃木県に06年11月に研究所
▽デュポン
 名古屋市に05年、樹脂などのマーケティング拠点
▽三菱化学
 三重県に3月、自動車メーカーと樹脂の共同開発拠点
▽三井化学
 4月、顧客別組織へ改正。自動車・産業材事業部を設置